We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-15.4%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.91B
AUM Growth
-$2.06B
Cap. Flow
+$62M
Cap. Flow %
0.63%
Top 10 Hldgs %
40.04%
Holding
153
New
17
Increased
26
Reduced
29
Closed
21

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$123M
2
WMGI
Wright Medical Group Inc
WMGI
+$120M
3
LLY icon
Eli Lilly
LLY
+$107M
4
HCA icon
HCA Healthcare
HCA
+$72.7M
5
DVAX
Dynavax Technologies
DVAX
+$70M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$161M
2
SHPG
Shire pic
SHPG
+$153M
3
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$120M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$119M
5
GILD icon
Gilead Sciences
GILD
+$79M

Sector Composition

Rank Sector Weight
1 Healthcare 92.06%
2 Financials 0.24%
3 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
101
MacroGenics
MGNX
$245M
$6.79M 0.07%
317,000
– –
ADXS
102
DELISTED
Advaxis Inc
ADXS
$6.51M 0.07%
42,440
-7,900
-16% -$1.91M
SAGE
103
DELISTED
Sage Therapeutics
SAGE
$6.35M 0.06%
149,999
-1
-0% -$62
ROKA
104
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$6.28M 0.06%
322,043
– –
ANAC
105
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$6.27M 0.06%
53,300
-75,700
-59% -$9.89M
IOVA icon
106
Iovance Biotherapeutics
IOVA
$2.1B
$5.89M 0.06%
1,022,100
– –
IMMU
107
DELISTED
Immunomedics Inc
IMMU
$5.72M 0.06%
+3,323,000
New +$8.48M
HZNP
108
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.04M 0.04%
204,000
-747,000
-79% -$23.6M
RCKT icon
109
Rocket Pharmaceuticals
RCKT
$343M
$4M 0.04%
+106,250
New +$4.88M
VTAE
110
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$3.98M 0.04%
+361,500
New +$3.84M
ASND icon
111
Ascendis Pharma A/S
ASND
$16.7B
$3.93M 0.04%
222,223
-1,226,768
-85% -$23.9M
FATE icon
112
Fate Therapeutics
FATE
$270M
$3.69M 0.04%
692,900
– –
BITI
113
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$3.52M 0.04%
268,672
– –
PTX
114
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$3.39M 0.03%
107,300
– –
ALIM
115
DELISTED
Alimera Sciences
ALIM
$3.31M 0.03%
100,000
– –
NVTA
116
DELISTED
Invitae Corporation
NVTA
$3.3M 0.03%
456,666
– –
OCUL icon
117
Ocular Therapeutix
OCUL
$1.85B
$2.94M 0.03%
+208,900
New +$4.2M
XYLO
118
DELISTED
Xylo Technologies
XYLO
$2.69M 0.03%
+375
New +$2.49M
ADAP
119
DELISTED
Adaptimmune Therapeutics
ADAP
$2.11M 0.02%
176,470
-4,234,716
-96% -$59.8M
BLRX
120
BioLineRX
BLRX
$12.2M
$1.59M 0.02%
1,731
-161
-9% -$172K
XTNT icon
121
Xtant Medical Holdings
XTNT
$59.7M
$1.55M 0.02%
39,620
– –
MNKD icon
122
PUT
MannKind Corp
MNKD
$1.21B
$1.45M 0.01%
90,000
– –
QLTI
123
DELISTED
QLT Inc
QLTI
$1.33M 0.01%
500,000
– –
CGNT
124
DELISTED
Cogentix Medical, Inc.
CGNT
$1.23M 0.01%
990,745
– –
AMRN
125
Amarin Corp
AMRN
$293M
$676K 0.01%
17,500
– –
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2015 Portfolio in Review

As of Q3 2015, OrbiMed held 153 positions worth $9.91B, down 17% from $12B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed's Q3 2015 filing shows 17 new, 26 increased, 29 reduced and 21 closed positions. Its largest new stake was Eli Lilly: 1,272,000 shares worth $106M. The largest sale was MEDIVATION, INC., an estimated $161M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 87% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q3 2015 buy was Eli Lilly: 1,272,000 shares worth $106M.
  • OrbiMed added most to Teva Pharmaceuticals in Q3 2015, an estimated $123M increase.
  • OrbiMed's biggest Q3 2015 reduction was Shire pic, cutting an estimated $153M.
  • OrbiMed fully exited MEDIVATION, INC. in Q3 2015, selling an estimated $161M.
  • OrbiMed's ten largest holdings make up 40% of its $9.91B portfolio in Q3 2015.
  • OrbiMed opened 17 new positions and closed 21 in Q3 2015.
  • OrbiMed's portfolio value fell 17% quarter-over-quarter to $9.91B.

Based on OrbiMed's 13F filing for Q3 2015, filed 13 Nov 2015.